Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Expression of podoplanin and ABCG2 in oral erythroplakia correlate with oral cancer development.

Feng JQ, Mi JG, Wu L, Ma LW, Shi LJ, Yang X, Liu W, Zhang CP, Zhou ZT.

Oral Oncol. 2012 Sep;48(9):848-52. doi: 10.1016/j.oraloncology.2012.03.015. Epub 2012 Apr 22.

PMID:
22525603
2.

Podoplanin and ABCG2: malignant transformation risk markers for oral lichen planus.

Shi P, Liu W, Zhou ZT, He QB, Jiang WW.

Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):844-9. doi: 10.1158/1055-9965.EPI-09-0699. Epub 2010 Mar 3.

3.

Two stem cell markers, ATP-binding cassette, G2 subfamily (ABCG2) and BMI-1, predict the transformation of oral leukoplakia to cancer: a long-term follow-up study.

Liu W, Feng JQ, Shen XM, Wang HY, Liu Y, Zhou ZT.

Cancer. 2012 Mar 15;118(6):1693-700. doi: 10.1002/cncr.26483. Epub 2011 Aug 25.

4.

Expression of cancer stem cell markers ALDH1 and Bmi1 in oral erythroplakia and the risk of oral cancer.

Feng JQ, Xu ZY, Shi LJ, Wu L, Liu W, Zhou ZT.

J Oral Pathol Med. 2013 Feb;42(2):148-53. doi: 10.1111/j.1600-0714.2012.01191.x. Epub 2012 Jun 23.

PMID:
22725270
5.

Expression of ABCG2 and Bmi-1 in oral potentially malignant lesions and oral squamous cell carcinoma.

Dalley AJ, Pitty LP, Major AG, Abdulmajeed AA, Farah CS.

Cancer Med. 2014 Apr;3(2):273-83. doi: 10.1002/cam4.182. Epub 2014 Jan 11.

6.

Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.

Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman SM, Mao L.

J Clin Oncol. 2008 Jan 20;26(3):354-60. doi: 10.1200/JCO.2007.13.4072.

PMID:
18202409
7.

Expressions of ABCG2, CD133, and podoplanin in salivary adenoid cystic carcinoma.

Li W, Tamamura R, Wang B, Liu Q, Liu H, Liu T, Katase N, Xiao J, Nagatsuka H.

Biomed Res Int. 2014;2014:132349. doi: 10.1155/2014/132349. Epub 2014 Apr 6.

8.

Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma.

Hang D, Dong HC, Ning T, Dong B, Hou DL, Xu WG.

Dis Esophagus. 2012 Sep-Oct;25(7):638-44. doi: 10.1111/j.1442-2050.2011.01298.x. Epub 2012 Jan 11.

PMID:
22236447
9.

Podoplanin expression in oral leukoplakia: tumorigenic role.

de Vicente JC, Rodrigo JP, Rodriguez-Santamarta T, Lequerica-Fernández P, Allonca E, García-Pedrero JM.

Oral Oncol. 2013 Jun;49(6):598-603. doi: 10.1016/j.oraloncology.2013.02.008. Epub 2013 Mar 7.

PMID:
23473850
10.

ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma.

Tsunoda S, Okumura T, Ito T, Kondo K, Ortiz C, Tanaka E, Watanabe G, Itami A, Sakai Y, Shimada Y.

Oncology. 2006;71(3-4):251-8. Epub 2007 Jul 10.

PMID:
17671398
11.

Prognostic impact of membranous ATP-binding cassette Sub-family G member 2 expression in patients with colorectal carcinoma after surgical resection.

Kang D, Park JM, Jung CK, Lee BI, Oh ST, Choi MG.

Cancer Biol Ther. 2015;16(10):1438-44. doi: 10.1080/15384047.2015.1071736. Epub 2015 Jul 15.

12.

Podoplanin Expression Is Correlated With the Progression of Chronic Discoid Lupus Erythematosus to Lip Squamous Cell Carcinoma.

Gao X, Ma L, Zhou Z, Jian X, Liu W.

Int J Surg Pathol. 2016 Oct;24(7):595-9. doi: 10.1177/1066896916652220. Epub 2016 May 29.

PMID:
27240861
13.

Membranous ABCG2 expression in colorectal cancer independently correlates with shortened patient survival.

Wang X, Xia B, Liang Y, Peng L, Wang Z, Zhuo J, Wang W, Jiang B.

Cancer Biomark. 2013;13(2):81-8. doi: 10.3233/CBM-130344.

PMID:
23838136
14.

[Expression of ATP-binding cassette transporter ABCG2 in gastric carcinoma and its significance].

Wang N, Chen L, Wei B, Zhao XY, Lu WJ, Shen L.

Zhonghua Wei Chang Wai Ke Za Zhi. 2007 Sep;10(5):450-3. Chinese.

PMID:
17851787
15.
16.

ABCG2/V-ATPase was associated with the drug resistance and tumor metastasis of esophageal squamous cancer cells.

Huang L, Lu Q, Han Y, Li Z, Zhang Z, Li X.

Diagn Pathol. 2012 Dec 17;7:180. doi: 10.1186/1746-1596-7-180.

17.

Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.

Tang SC, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.

Int J Cancer. 2014 Mar 15;134(6):1484-94. doi: 10.1002/ijc.28475. Epub 2013 Oct 3.

18.
19.

Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.

Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR Jr, Fu LW, Ambudkar SV, Chen ZS.

Cancer Res. 2007 Nov 15;67(22):11012-20.

20.

[Expression and significance of ABCG2 in human malignant glioma].

Chu L, Huang Q, Zhai DZ, Zhu Q, Huo HM, Dong J, Qian ZY, Wang AD, Lan Q, Gao YL.

Ai Zheng. 2007 Oct;26(10):1090-4. Chinese.

PMID:
17927879

Supplemental Content

Support Center